Shingrix® is approved for use for the prevention of herpes zoster (shingles) and herpes zoster complications such as post herpetic neuralgia (PHN) in adults aged over 50 years.
PHN is a debilitating and painful condition, particularly in older people.
Two doses are funded at age 65 years.
It is recommended, but not funded, for all individuals aged from 50 years.
It is particularly recommended for individuals have an increased risk of zoster and zoster complications and for those who have contraindications to the live zoster vaccine (Zostavax).
The effectiveness of this vaccine does not decrease when given to older age groups (with an efficacy of around 90% against zoster and PHN), so those aged over 70 years will also be protected and a high level of protection (over 80%) has been shown to be maintained for more than seven years, so far.
For more information: https://www.immune.org.nz/vaccine/shingrix
To book Click below
